News
10-14-2008, 09:10 AM
Britain's healthcare cost effectiveness watchdog NICE has rebuffedGlaxoSmithKline's latest bid to get its drug Tyverb -- for womenwith advanced breast cancer -- into the state health system, thecompany said on Tuesday.
More... (http://www.healthcentral.com/breast-cancer/news-271779-66.html)
More... (http://www.healthcentral.com/breast-cancer/news-271779-66.html)